Axsome Submits sNDA for AXS-05 to Treat Agitation in Alzheimer Disease
Submission of the sNDA suggests a potential FDA decision on the dextromethorphan-bupropion combination sometime during the first quarter of 2026.
FMX 2025: 6 Takeaways for Primary Care Physicians
Explore key clinical takeaways from FMX 2025, including updates on CGM, chronic cough, AAA screening, immunization, and more.
Weekly Dose Podcast: Global Diabetes Gaps, Declining Salt Substitute Use, Flu Vaccine Safety, Vaginal Estradiol, and Preconception CT Risks
This new episode covers global diabetes gaps, salt substitute use, influenza vaccine safety, vaginal estradiol, and preconception CT risks.
Dupilumab Meets All Endpoints in Phase 3 Study for Allergic Fungal Rhinosinusitis; FDA Grants Priority Review
ACAAI 2025: Phase 3 results show dupilumab significantly reduced sinus opacification, nasal congestion, and polyp size in patients with AFRS.
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis: Daily Dose
Your daily dose of the clinical news you may have missed.
CagriSema Reduces SBP by 10.9 mmHg in Post Hoc Analysis of REDEFINE 1 Trial
Nearly 40% of REDEFINE 1 participants taking antihypertensive medications reduced or discontinued their blood pressure drugs during the trial, Novo Nordisk reported.
Diabetes Self-Management at Work: A Checklist for Clinicians
Adults with diabetes often face obstacles to optimal disease management in the workplace. Use this checklist in the clinic to help them navigate the barriers.
Hormone Therapy and Autoimmune Disease: Early Findings Raise New Questions for Postmenopausal Care
New research suggests hormone therapy may increase autoimmune disease risk in postmenopausal women. Dr Jiang discusses early findings and clinical implications.
Xuezhi Daniel Jiang, MD, PhD, on Counseling Postmenopausal Women on Autoimmune Disease Risk Without Creating Hormone Therapy Phobia
Jiang shares how to use new autoimmune risk data responsibly—identifying high-risk patients while avoiding unnecessary hormone therapy phobia.
Perimenopause Symptom Management is Never One-Size-Fits-All, Says Menopause Expert
TMS 2025: Dr Marla Shapiro doesn't start perimenopausal therapy without an answer to the most important question: "What is your most bothersome symptom?"
Administration Anounces Landmark GLP-1 Pricing Agreement with Eli Lilly and Novo Nordisk
Trump announces deals with Eli Lilly and Novo Nordisk slashing GLP-1 prices to as low as $150/month, expanding Medicare coverage starting mid-2026.
Oral Semaglutide 25 mg Shows Cardiometabolic Benefits Beyond Weight Loss in OASIS 4 Analysis
Oral semaglutide 25 mg improved glucose control and CV risk factors across weight loss categories in OASIS 4 post hoc analysis presented at ObesityWeek 2025.
Lumateperone Gets FDA Nod as Adjunctive Therapy for Major Depressive Disorder
As adjunctive treatment, lumateperone is associated with early symptom improvement, good tolerability, and provides a practical no-titration option for adults with persistent MDD.
Wegovy Users More Likely to Reach Key Obesity Treatment Targets, STEP UP Study Finds
Novo Nordisk’s STEP UP trial shows semaglutide delivers 21% weight loss and reduces key cardiovascular and metabolic risk factors in obesity management.
Moderate-to-Severe OSA Linked to Doubled Risk of Brain Microbleeds Over 8 Years: New Research
New longitudinal data from a Korean cohort suggest OSA may be an independent risk factor for cerebral small vessel disease.
5 Novel Mechanisms Reshaping Atopic Dermatitis Treatment and the Phase 2-3 Clinical Trials That Support Them
Novel AD therapies targeting OX40, IL-13, IL-36, IL-22, and IL-2 pathways show promise for disease modification and extended dosing intervals in phase 2-3 trials.
The Hidden Toll of Diabetes in the Workplace: Global Survey Data
Global survey data highlight persistent stigma and self-management barriers for adults with diabetes in the workplace, with implications for clinical care.
FDA Approves Simplified Once-Monthly Mirikizumab-mrkz Regimen for Ulcerative Colitis Maintenance Therapy
The FDA approves a single monthly injection of mirikizumab-mrkz for ulcerative colitis, enhancing patient convenience and addressing bowel urgency effectively.
Complementary Studies Point to How to Boost CRC Screening Rates
Patient preferences favor home-based tests but MDs do not, while cost barriers significantly impact follow-up completion, according to the 2 new analyses.
Blood Glucose Levels in T2D: 42 Factors that Make A Difference
These 42 factors that affect blood glucose are in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.
FAQs on Cardiac Rehab in Women for Primary Care Clinicians
Women experience greater CR mortality benefits than men yet have 36% lower enrollment. New AHA statement addresses barriers across the care continuum.
Lisa Larkin, MD: Elinzanetant Offers a “Game-Changing” Option for Menopause Care in Primary Care
Lisa Larkin, MD, discusses how elinzanetant may change menopause management for women who can’t use hormone therapy and what PCPs need to know.
Facility-Based CRC Screening Nearly 10-Fold Higher in 45- to 49-Year-Olds After Guideline Changes
Colorectal cancer screenings for 45- to 49-year-olds surge nearly tenfold after new guidelines, highlighting significant shifts in public health practices.
FDA Approves New Treatment for Acromegaly: Daily Dose
Perimenopausal Brain Fog: A Frequent Complaint That Needs a Compassionate Response, Says Marla Shapiro, CM, CCFP, MHSc
"If you don't know where your keys are, that's fine." Shapiro's memorable analogy helps distinguish perimenopause brain fog from serious cognitive concerns.
GLP-1 Receptor Agonist GI Safety Comparable Within the Class, But Exceeds SGLT-2 Inhibitor Risk
The real-world study of 200,000+ adults found no GI safety differences among 3 GLP-1 drugs for T2D, however SGLT-2 inhibitors are safer for motility issues.
Tezepelumab Achieves Dual Benefit in Severe Asthma, Improving Control with Reduced Steroid Dependence
WAYFINDER: 90% of steroid-dependent severe asthma patients reduced to ≤5mg daily on tezepelumab. Well-controlled asthma increased from 3% to 27% at 52 weeks.
EPIC-Norfolk Study Supports Universal Screening for Three Cardiovascular Biomarkers
Three-biomarker panel independently predicted cardiovascular events over 20 years in European cohort, with highest risk when all 3 were elevated.
Quiz: Recent Advances in Menopause and Midlife Women’s Health Research
A quick quiz covering new research on menopause hormone therapy, Alzheimer risk, tirzepatide weight loss, and estetrol’s cardiovascular safety.
Aggressive Risk Factor Management Reduced Recurrent AF by Nearly Half After Catheter Ablation
The rate of AF recurrence was reduced significantly and participants also experienced improvements in self-reported AF severity as well as improved cardiometabolic measures.
